

Author's Proof

Before checking your proof, **please see the instructions below.**

- Carefully read the entire proof and mark all corrections in the appropriate place, using the Adobe Reader commenting tools ([Adobe Help](#)).
- Provide your corrections in a single PDF file or post your comments in the Production Forum making sure to reference the relevant query/line number. Upload or post all your corrections directly in the Production Forum to avoid any comments being missed.
- We do not accept corrections in the form of edited manuscripts nor via email.
- Do not provide scanned, handwritten corrections.
- Before you submit your corrections, please make sure that you have checked your proof carefully as once you approve it, you won't be able to make any further corrections.
- To ensure the timely publication of your article, please submit the corrections within 48 hours. After submitting, do not email or query asking for confirmation of receipt.

Do you need help? Visit our [Production Help Center](#) for more information. If you can't find an answer to your question, contact your Production team directly by posting in the Production Forum.

Quick checklist

- Author names** - Complete, accurate and consistent with your previous publications.
- Affiliations** - Complete and accurate. Follow this style when applicable: Department, Institute, University, City, Country.
- Tables** - Make sure our formatting style did not change the meaning/alignment of your Tables.
- Figures** - Make sure we are using the latest versions.
- Funding and Acknowledgments** - List all relevant funders and acknowledgments.
- Conflict of Interest** - Ensure any relevant conflicts are declared.
- Supplementary files** - Ensure the latest files are published and that no line numbers and tracked changes are visible. Also, the supplementary files should be cited in the article body text.
- Queries** - Reply to all typesetters queries below.
- Content** - Read all content carefully and ensure any necessary corrections are made.

Author queries form

Query No.	Details Required	Author's Response
Q1	The citation and surnames of all of the authors have been highlighted. Check that they are correct and consistent with your previous publications, and correct them if needed. Please note that this may affect the indexing of your article in repositories such as PubMed. If adding/removing authors, or changing the order of this list, please provide us with a signed Authorship Change form .	
Q2	Confirm whether the article title is correct.	
Q3	Check that the amendments made to the title are satisfactory.	

Query No.	Details Required	Author's Response
Q4	<p>Confirm that all author affiliations are correctly listed. Per our style guidelines, affiliations are listed sequentially and follow author order. Requests for non-sequential affiliation listing will not be fulfilled. Note that affiliations should reflect those at the time during which the work was undertaken.</p> <p>If adding new affiliations, specify if these should be listed as a present address instead of a regular affiliation.</p>	
Q5	<p>Confirm that the email address in your correspondence section is accurate. Any changes to corresponding authors requires individual confirmation from all original and added/removed corresponding authors.</p>	
Q6	<p>The abstract should ideally be structured according to the IMRaD format (Introduction, Methods, Results and Discussion). Provide a structured abstract if possible.</p>	
Q7	<p>Confirm that the keywords are correct, and keep them to a maximum of eight and a minimum of five. (Note: a keyword can be made up of one or more words.)</p>	
Q8	<p>Check if the section headers (i.e., section leveling) have been correctly captured.</p>	
Q9	<p>Check that all equations and special characters are displayed correctly.</p>	
Q10	<p>Please confirm whether the edits made in the following sentence is fine. "Expression levels in each sample were calculated using the Efficiency adjusted Ct of the normalizer gene (B2M)—Efficiency adjusted Ct of the target gene (comparative $-\Delta\text{Ct}$ method). Normal/gaussian distribution of the values was assessed using the Shapiro–Wilk test."</p>	
Q11	<p>Ensure that all the figures, tables, and captions are correct, and that all figures are of the highest quality/resolution. If necessary, you may upload improved figures to the Production Forum. Please note that figures and tables must be cited sequentially, per section 2.2 of the author guidelines.</p>	
Q12	<p>If you decide to use previously published, copyrighted figures in your article, please keep in mind that it is your responsibility as the author to obtain the appropriate permissions and licenses to reproduce them, and to follow any citation instructions requested by third-party rights holders. If obtaining the reproduction rights involves the payment of a fee, these charges are to be paid by the authors.</p>	
Q13	<p>Provide the meaning of the bold values provided in Table 3.</p>	
Q14	<p>Confirm that the Data Availability statement is accurate. Note that this statement may have been amended to adhere to our Publication Ethics guidelines.</p>	

Query No.	Details Required	Author's Response
Q15	Your article contains an invalid Data Availability Statement. See our Materials and Data Policies here , provide a suitable data statement based on the data type in your manuscript. Authors are required to make certain types of data available to readers at the time of publication in specific, stable, community-supported repositories. If your article contains mandatory data, the revised Data Availability Statement should include the accession number(s) and a direct link/ URL to this data.	
Q16	If your article requires an Ethics statement, please confirm that the statement in this proof is correct. If this is not the latest version, please provide a revised Ethics statement. If your article contains identifiable human images, please check our Policies and Publication Ethics here .	
Q17	Confirm that the details in the "Author Contributions" section are correct. We have added the sentence "All authors contributed to the article and approved the submitted version."	
Q18	Ensure all grant numbers and funding information are included and accurate (after publication it is not possible to change this information). All funders should be credited, and all grant numbers should be correctly included in this section.	
Q19	Confirm if the text included in the Conflict of Interest statement is correct. Please do not suggest edits to the wording of the final sentence, as this is standard for Frontiers' journal style.	
Q20	Frontiers guidelines require listing the first 6 authors + et al. for articles with more than 6 authors. Please provide the names of the other authors for "Wei et al., 2022, Zhao et al., 2022, Tang et al., 2022, Zemmour et al., 2017."	
Q21	Provide the editor name(s), publisher location, and name for "Xu et al., 2021."	



OPEN ACCESS

EDITED BY

Alan Yiu Wah Lee,
Monash University Malaysia, Malaysia

REVIEWED BY

Paolo Follesa,
University of Cagliari,
Italy
Amin Safa,
Complutense University of Madrid, Spain

*CORRESPONDENCE

Soudeh Ghafouri-Fard
✉ s.ghafourifard@sbmu.ac.ir
Arezou Sayad
✉ ar.sayad@yahoo.com

SPECIALTY SECTION

This article was submitted to
Brain Disease Mechanisms,
a section of the journal
Frontiers in Molecular Neuroscience

RECEIVED 29 August 2022

ACCEPTED 14 December 2022

PUBLISHED xx xx 2022

CITATION

Sharifi G, Eghtedarian R, Taheri M,
Hussen BM, Eslami S, Ghafouri-Fard S and
Sayad A (2022) Assessment of Treg-related
lncRNAs in epilepsy.
Front. Mol. Neurosci. 15:1031314.
doi: 10.3389/fnmol.2022.1031314

COPYRIGHT

© 2022 Sharifi, Eghtedarian, Taheri, Hussen,
Eslami, Ghafouri-Fard and Sayad. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Assessment of Treg-related lncRNAs in epilepsy

Guive Sharifi¹, Reyhane Eghtedarian², Mohammad Taheri^{3,4},
Bashdar Mahmud Hussen^{5,6}, Solat Eslami^{7,8},
Soudeh Ghafouri-Fard^{9*} and Arezou Sayad^{10*}

¹Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ²Phytochemistry Research Center, Shahid Beheshti University of Sciences, Tehran, Iran, ³Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ⁴Institute of Human Genetics, Jena University Hospital, Jena, Germany, ⁵Department of Pharmacognosy, College of Pharmacy, Hawler Medical University, Erbil, Iraq, ⁶Center of Research and Strategic Studies, Lebanese French University, Erbil, Iraq, ⁷Department of Medical Biotechnology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran, ⁸Dietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Karaj, Iran, ⁹Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ¹⁰Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Recent studies have shown dysregulation of several groups of long non-coding RNAs in the context of epilepsy. According to evidence regarding the role of regulatory T cells in this disorder, we examined expression levels of regulatory T cell-related lncRNAs, namely TH2-LCR, RMRP, IFNG-AS1 (NEST), MAFTRR and FLICR in the blood of epileptic cases compared with controls. Expression of RMRP was lower in patients with refractory epilepsy compared with controls [expression ratio (95% CI)=0.32 (0.13–0.8), adjusted p -value=0.0008]. Besides, its expression was lower in refractory patients vs. non-refractory patients [expression ratio (95% CI)=0.2 (0.1–0.41), adjusted p -value < 0.0001]. Expression of TH2-LCR was lower in refractory patients vs. controls [expression ratio (95% CI)=0.4 (0.17–0.93), adjusted p -value=0.0044] and in refractory patients vs. non-refractory ones [Expression ratio=0.28 (0.19–0.58), p -value < 0.0001]. Expression of NEST was higher in total patients [expression ratio (95% CI)=2.48 (1.15–5.27), adjusted p -value=0.0012] and in both groups of patients compared with controls. However, its expression was not different between refractory and non-refractory cases. Similarly, FLICR and MAFTRR were over-expressed in total cases and both groups of patients compared with controls, but their expressions were similar between refractory and non-refractory cases. MAFTRR could differentiate between total epileptic cases and controls with AUC value of 0.8. This lncRNA could separate refractory and non-refractory cases from healthy controls with AUC values of 0.73 and 0.88, respectively. This study provides evidence for deregulation of regulatory T cell-related lncRNAs in epilepsy and their potential role as diagnostic markers in this condition.

KEYWORDS

epilepsy, lncRNA, TH2-LCR, RMRP, IFNG-AS1 (NEST), MAFTRR, FLICR

Q2 50
Q3 51
52
53
54
Q1 55
56
57
58
Q4 59
60
61
62
63
64
65
66
67
Q6 68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
Q7 94
95
96
97
98

Introduction

Epilepsy is a complex condition with several known and unknown background, among them being abnormal activity of the immune system. Immune activation that results in functional rewiring of the brain has been shown to be the cause or effect of seizure (Xu et al., 2021). A bulk of evidence has revealed the functional roles of regulatory immune cells in the modulation seizures as well as in the epileptogenic processes (Xu et al., 2021). CD4 + FoxP3+ regulatory T cells (Tregs) have a particular role in this condition. Depletion of brain Tregs can lead to exacerbation of hippocampal neuroinflammation and induction of oxidative stress following status epilepticus (Yue et al., 2022). Moreover, it can reduce survival hippocampal neurons and aggravate seizure activity. Therefore, amplification of brain Tregs has been regarded as an antiepileptic strategy in animal models (Yue et al., 2022). Another study in rat models of temporal lobe epilepsy has shown the important roles of Th17, Tregs, and related cytokines in this disorder and suggested the efficacy of balancing Th17 and Tregs as a therapeutic option for patients with epilepsy (Wei et al., 2022).

In addition, a group of studies has highlighted contribution of long non-coding RNAs (lncRNAs) in the epileptogenic processes (Hashemian et al., 2019; Villa et al., 2019). These epigenetic factors regulate the pathophysiological process of epilepsy and have been found to be dysregulated during epileptogenesis. Experiments in human subjects affected with epilepsy and in animal models of this disorder have shown abnormal expression of non-coding RNAs (Manna et al., 2022). Based on the importance of lncRNAs in the regulation of Treg functions (Luo and Wang, 2020), we have selected five Treg-related lncRNAs to assess their expression in patients with epilepsy. These lncRNAs are FLICR (FOXP3 Regulating Long Intergenic Non-Coding RNA), NEST (IFNG-AS1), RMRP (RNA Component of Mitochondrial RNA Processing Endoribonuclease), MAFTRR (MAF Transcriptional Regulator RNA) and TH2-LCR (Th2 Cytokine Locus Control Region).

Materials and methods

Enlisted subjects

Eighty epileptic patients and 50 normal individuals were recruited in the current study. Cases were diagnosed based on electroencephalogram and brain MRI. Those included in the non-refractory group had no seizures throughout 6 months prior to sampling. Patients with refractory seizure had seizures in spite of taking appropriate doses of at least three antiepileptic medications. The study was approved by the ethical committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.RETECH.REC.1400.337). Informed consent was signed by all participants. Controls had no neurological, psychiatric or systemic diseases.

Experiments

Total RNA was retrieved from whole blood samples using the RNJia Kit (ROJE Technologies, Tehran, Iran). Then, 50 ng of extracted RNA was used for production of cDNA using AddScript cDNA synthesis kit (AddBio, Korea). Expressions of FLICR, MAFTRR, NEST, RMRP and TH2-LCR were quantified in patients and controls using Ampliqon master mix (Denmark). Reactions were performed in StepOnePlus Real-Time PCR System. B2M was used as normalizer (reference gene for qPCR) in a way that transcript levels of all genes were calculated in relation with expression levels of B2M in each sample. Information about primers is shown in Table 1.

Statistical analyses

GraphPad Prism version 9.0 (La Jolla, CA, United States) was used for statistical analysis. We compared expressions of five Treg-related lncRNA genes including TH2-LCR, RMRP, IFNG-AS1 (NEST), MAFTRR and FLICR in peripheral blood samples obtained from patients with epilepsy (40 refractory cases and 40 non-refractory cases) and 50 healthy controls. Expression levels in were calculated using the Efficiency adjusted Ct values. Expression levels in each sample were calculated using the Efficiency adjusted Ct of the normalizer gene (B2M)—Efficiency adjusted Ct of the target gene (comparative $-\Delta\text{Ct}$ method). Normal/gaussian distribution of the values was assessed using the Shapiro–Wilk test.

TABLE 1 Primer sequences and corresponding amplified regions.

Gene	Sequence 5→3	Primer length (bp)
<i>B2M</i>	F-AGATGAGTATGCCTGCCGTG	20
	R-GCGGCATCTTCAAACCTCCA	20
<i>FLICR</i>	F-GGG CTT TTC CAG AAG GGT CT	20
	R-AGC CCA GGG TTC TAG TCG	18
<i>MAFTRR</i>	F-CTG AAG GGA CAG GAC GGA CAA C	22
	R-GGG GAA AAC CTG GAA AGA GGG A	22
<i>NEST</i>	F-AGC TGA TGA TGG TGG CAA TCT	21
	R-TGA CTT CTC CTC CAG CGT TTT	21
<i>RMRP</i>	F-GTA GAC ATT CCC CGC TTC CCA	21
	R-GAG AAT GAG CCC CGT GTG GTT	21
<i>TH2-LCR</i>	F-GCT CCC CAG GCT TTT GAG ATA	21
	R-TGG TGA TGC TGA AGG GAG AC	20

Differentially expressed genes were identified using Kruskal–Wallis test. This analysis was repeated for all comparisons (refractory epilepsy, non-refractory epilepsy, and total epilepsy patients vs. healthy controls).

Correlation between gene expression levels in patients and control samples was assessed using Spearman’s rank correlation coefficient since data was not normally distributed.

Receiver operating characteristic (ROC) curve was illustrated to appraise diagnostic power of expression levels of differentially expressed genes. *p*-value < 0.05 was considered as significant. This type of analysis was used for assessment of the performance of expression levels of genes as diagnostic tests. It functions as a simple graphical tool for showing the accuracy of a medical diagnostic test.

TABLE 2 Sex ratio of cases with epilepsy.

Groups	Refractory group	Non-refractory group
Total, number (%)	40 (33.33)	40 (33.33)
Male, number (%)	17(29.31)	24 (41.38)
Female, number (%)	23 (37.1)	16 (25.8)

Age (mean ± SD) values of controls, refractory patients, and non-refractory patients were 33.93 ± 9.04, 36.75 ± 7.75, and 32.70 ± 11.89, respectively.

Results

General information

Table 2 shows the sex ratio of patients with refractory and non-refractory seizure.

Expression assays

Significant differences were detected in expression of RMRP, TH-2LCR, NEST, MAFTRR, and FLICR between certain study subgroups (Figure 1).

Expression of RMRP was lower in patients with refractory epilepsy compared with controls [expression ratio (95% CI) = 0.32 (0.13–0.8), adjusted *p*-value = 0.0008]. Besides, its expression was lower in refractory patients vs. non-refractory patients [expression ratio (95% CI) = 0.2 (0.1–0.41), adjusted *p*-value < 0.0001]. Expression of TH2-LCR was lower in refractory patients vs. controls [expression ratio (95% CI) = 0.4 (0.17–0.93), adjusted *p*-value = 0.0044] and in refractory patients vs. non-refractory ones [Expression ratio = 0.28 (0.19–0.58), *p*-value < 0.0001]. Expression of NEST was higher in total patients [expression ratio (95% CI) = 2.48 (1.15–5.27), adjusted *p*-value = 0.0012] and in




FIGURE 1

Relative expression levels of five Treg-related lncRNAs in epilepsy patients (total), refractory epilepsy, non-refractory epilepsy and healthy controls as described by $-\Delta Ct$ values. $-\Delta Ct$ Data were plotted as box and whisker plots showing the median [line], mean [cross], interquartile range [box], and minimum and maximum values. A non-parametric Kruskal–Wallis test was used to identify differentially expressed genes between patients (refractory epilepsy, non-refractory epilepsy and total epilepsy patients) and healthy controls (**p*-values < 0.05, ***p*-values < 0.01, ****p*-values < 0.001, and *****p*-values < 0.0001).

Q11

Q13

TABLE 3 Results of expression study of five Treg-related lncRNAs, namely RMRP, TH2-LCR, NEST, MAFTRR, and FLICR in peripheral blood of patients with epilepsy (refractory and non-refractory groups) compared with healthy controls.

Studied genes		Total epilepsy patients vs. controls (80 vs. 50)	Refractory patients vs. controls (40 vs. 50)	Non-refractory patients vs. controls (40 vs. 50)	Refractory patients vs. non-refractory patients (40 vs. 40)
RMRP	Expression ratio (95% CI)	0.72 (0.34–1.48)	0.32 (0.13–0.8)	1.57 (0.83–1.56)	0.2 (0.1–0.41)
	Adjusted <i>P</i> -value	>0.9999	0.0008	0.1516	<0.0001
TH2-LCR	Expression ratio(95% CI)	0.69 (0.33–1.4)	0.4 (0.17–0.93)	1.18 (0.6–2.29)	0.28 (0.19–0.58)
	Adjusted <i>P</i> -value	>0.9999	0.0044	0.9499	<0.0001
NEST	Expression ratio (95% CI)	2.48 (1.15–5.27)	2.34 (1.1–4.94)	2.48 (1.15–5.27)	0.94 (0.42–2.12)
	Adjusted <i>P</i> -value	0.0012	0.0021	0.0012	>0.9999
FLICR	Expression ratio (95% CI)	6.77 (2.41–19.02)	6.58 (2.01–21.55)	6.96 (2.02–24.08)	0.94 (0.29–3.01)
	Adjusted <i>P</i> -value	<0.0001	0.0003	<0.0001	>0.9999
MAFTRR	Expression ratio (95% CI)	26.5 (7.21–96.8)	13.08 (2.82–60.67)	53.48 (13.62–208.51)	0.24 (0.07–0.8)
	Adjusted <i>P</i> -value	<0.0001	0.0051	<0.0001	0.0126

The expression ratio of each gene is shown as mean and 95% Confidence interval (95% CI). Numbers in column identifiers indicate the number of persons in each group being compared.

both groups of patients compared with controls. However, its expression was not different between refractory and non-refractory patients. Similarly, FLICR and MAFTRR were over-expressed in total cases and both groups of patients compared with controls, but their expressions were similar between refractory and non-refractory patients (Table 3).

Expression of NEST was correlated with expressions of TH2-LTR and RMRR in healthy controls (correlation coefficients = 0.32 and 0.35, respectively). Moreover, expression of FLICR was correlated with TH2-LCR expression in non-refractory and controls groups (correlation coefficients = 0.46 and 0.44, respectively) and with MAFTRR levels in non-refractory group (correlation coefficient = 0.31). Finally, expression of TH2-LCR was correlated with MAFTRR level in refractory and non-refractory groups (correlation coefficients = 0.71 and 0.37, respectively) and with RMRP level in non-refractory patients (correlation coefficient = 0.44; Table 4).

MAFTRR could differentiate between total epileptic cases and controls with AUC value of 0.8. This lncRNA could separate refractory and non-refractory cases from healthy controls with AUC values of 0.73 and 0.88, respectively (Figure 2; Table 5).

Discussion

lncRNAs can affect pathophysiology of epilepsy through different mechanisms among them is regulation of immune responses (Zhao et al., 2022). Tregs have fundamental roles in the regulation of immune activity and are involved in the suppression of epileptogenesis (Xu et al., 2021). Therefore, Treg-related lncRNAs are putative candidates for identification of the underlying mechanism of epilepsy. In the current research project, we compared expressions of five of these lncRNAs between epileptic cases and healthy subjects.

Expressions of RMRP and TH2-LCR were lower in refractory patients vs. controls and vs. non-refractory ones. RMRP has been shown to be over-expressed in some immune-related conditions (Hussen et al., 2021). Expression of this lncRNA has been up-regulated in T cells of rheumatoid arthritis cases and it has been correlated with duration of the disorder (Moharamoghli et al., 2019). On the other hand, RMRP has been shown to be under-expressed in major depressive disorder cases in correlation with severity of disorder (Seki et al., 2019). RMRP is also involved in the regulation of neuron apoptosis since it can accelerate autophagy-mediated apoptosis of neurons via modulation of miR-3,142/TRIB3 axis (Tang et al., 2022). TRIB3 has a putative role in epileptogenesis, since its inhibition can protect against kainic acid-induced neurotoxic injuries (Zhang et al., 2019). Thus, RMRP contributes to the pathogenesis of epilepsy through immune-related and -unrelated mechanisms.

TH2-LCR is involved in the modulation of production of Th2 cytokines (Koh et al., 2010). The impact of cytokines in the epilepsy has been revealed for many years. Over-expression of IL-1 β , TNF- α , and IL-6 have been reported in experimental models of seizures (Vezzani et al., 2008).

On the other hand, NEST, FLICR, and MAFTRR were over-expressed in total cases and both groups of patients compared with controls, but their expressions were similar between refractory and non-refractory patients. FLICR modulates expression of Foxp3 and facilitate development of a subgroup of Tregs with low expression of Foxp3 (Zemmour et al., 2017). NEST has a regulatory effect on methylation of the *IFN-G* locus; thus it modulates expression of IFN- γ (Gomez et al., 2013). In addition, NEST can reduce Th1-related proliferation of Tregs (Luo et al., 2017). IFN- γ has been among cytokines whose postictal and interictal levels have been higher in epilepsy patients compared with healthy subjects (Gao et al., 2017). Moreover, interictal IL-IFN- γ levels could predict severity of seizures (Gao et al., 2017).

TABLE 4 Spearman's correlations between expression levels of five lncRNA among refractory epilepsy patients (N=40), non-refractory epilepsy patients (N=40), and healthy controls (N=50).

	FLICR			TH2LCR			MAFTRR			RMRP		
	Refractory	Non-refractory	Healthy controls	Refractory	Non-refractory	Healthy controls	Refractory	Non-refractory	Healthy controls	Refractory	Non-refractory	Healthy controls
NEST	0.08	0.22	0.21	-0.017	0.17	0.32*	-0.01	-0.01	0.1	0.55**	0.4	0.35*
FLICR				0.20	0.46*	0.44*	0.20	0.31*	0.07	0.069	0.14	0.07
TH2LCR							0.71**	0.37*	0.14	-0.24	0.44*	0.16
MAFTRR										-0.22	0.1	0.17

* $p < 0.05$, ** $p < 0.001$.

TABLE 5 ROC curve analysis in patients with total epilepsy cases, refractory epilepsy patients, and non-refractory epilepsy patients.

	MAFTRR				FLICR				NEST				TH2-LCR				RMRP			
	AUC±SD	Sensitivity	Specificity	p-value	AUC±SD	Sensitivity	Specificity	p-value	AUC±SD	Sensitivity	Specificity	p-value	AUC±SD	Sensitivity	Specificity	p-value	AUC±SD	Sensitivity	Specificity	p-value
Total cases vs. healthy normal controls (80 vs. 50)	0.8±0.04	0.92	0.56	<0.000	0.76±0.04	0.83	0.74	<0.00	0.73±0.04	0.77	0.66	<0.000	0.56±0.05	0.93	0.28	0.25	0.54±0.05	0.92	0.28	0.35
Refractory patients vs. controls (40 vs. 50)	0.73±0.05	0.92	0.5	0.0002	0.76±0.05	0.87	0.62	<0.0001	0.73±0.05	0.82	0.68	0.0002	0.68±0.05	0.67	0.68	0.002	0.72±0.05	0.9	0.46	0.0004
Non-refractory patients vs. healthy controls (40 vs. 50)	0.88±0.03	0.92	0.66	<0.0001	0.75±0.05	0.65	0.8	<0.0001	0.72±0.05	0.75	0.64	0.0003	0.56±0.06	0.95	0.38	0.29	0.62±0.06	0.92	0.48	0.04




FIGURE 2

ROC curves of five Treg-related lncRNAs, namely RMRP, TH-2LCR, NEST, MAFTRR and FLICR in total epilepsy cases (A), Refractory epilepsy patients (B), and non-refractory epilepsy patients (C).

Expression of NEST was correlated with expressions of TH2-LTR and RMRR in healthy controls. Moreover, expression of FLICR was correlated with TH2-LCR expression in non-refractory and controls groups and with MAFTRR levels in non-refractory group. Finally, expression of TH2-LCR was correlated with MAFTRR level in refractory and non-refractory groups and with RMRP level in non-refractory patients. This data shows a trend toward disease-specific pattern of correlation which can be different among refractory and non-refractory cases. Future studies are needed to show whether this pattern can affect response of patients to antiepileptic drugs.

MAFTRR could differentiate between total epileptic cases and controls with AUC value of 0.8. This lncRNA could separate refractory and non-refractory cases from healthy controls with AUC values of 0.73 and 0.88, respectively. Therefore, MAFTRR can be regarded as a diagnostic marker for epilepsy, particularly non-refractory epilepsy.

This study provides evidence for dysregulation of regulatory T cell-related lncRNAs in epilepsy and their potential role as diagnostic markers in this condition. Further studies are needed to assess expression of these ncRNAs in other biofluids and find possible correlations between their expression levels in the brain, lymphocyte, and saliva.

Data availability statement

The authors acknowledge that the data presented in this study must be deposited and made publicly available in an acceptable repository, prior to publication. Frontiers cannot accept a manuscript that does not adhere to our open data policies.

Ethics statement

The study protocol was approved by the ethical committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.

RETECH.REC.1400.337). The patients/participants provided their written informed consent to participate in this study.

Author contributions

SG-F wrote the manuscript and revised it. MT and AS designed and supervised the study. BH, RE, and GS collected the data and performed the experiment. SE analyzed the data. All authors contributed to the article and approved the submitted version.

Acknowledgments

The authors would like to thank the Clinical Research Development Unit (CRDU) of Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran for their support, cooperation and assistance throughout the period of study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Gao, F., Gao, Y., Zhang, S. J., Zhe, X., Meng, F. L., Qian, H., et al. (2017). Alteration of plasma cytokines in patients with active epilepsy. *Acta Neurol. Scand.* 135, 663–669. doi: 10.1111/ane.12665
- Gomez, J. A., Wapinski, O. L., Yang, Y. W., Bureau, J. F., Gopinath, S., Monack, D. M., et al. (2013). The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon- γ locus. *Cells* 152, 743–754. doi: 10.1016/j.cell.2013.01.015
- Hashemian, F., Ghafouri-Fard, S., Arsang-Jang, S., Mirzajani, S., Fallah, H., Mehvari Habibabadi, J., et al. (2019). Epilepsy is associated with dysregulation of long non-coding RNAs in the peripheral blood. *Front. Mol. Biosci.* 6:113. doi: 10.3389/fmolb.2019.00113
- Hussen, B. M., Azimi, T., Hidayat, H. J., Taheri, M., and Ghafouri-Fard, S. (2021). Long non-coding RNA RMRP in the pathogenesis of human disorders. *Front. Cell Dev. Biol.* 9:676588. doi: 10.3389/fcell.2021.676588
- Koh, B. H., Hwang, S. S., Kim, J. Y., Lee, W., Kang, M. J., Lee, C. G., et al. (2010). Th2 LCR is essential for regulation of Th2 cytokine genes and for pathogenesis of allergic asthma. *Proc. Natl. Acad. Sci.* 107, 10614–10619. doi: 10.1073/pnas.1005383107
- Luo, M., Liu, X., Meng, H., Xu, L., Li, Y., Li, Z., et al. (2017). IFNA-AS1 regulates CD4+ T cell activation in myasthenia gravis through HLA-DRB1. *Clin. Immunol.* 183, 121–131. doi: 10.1016/j.clim.2017.08.008
- Luo, Y., and Wang, H. (2020). Effects of non-coding RNA on regulatory T cells and implications for treatment of immunological diseases. *Front. Immunol.* 11:612060. doi: 10.3389/fimmu.2020.612060
- Manna, I., Fortunato, F., de Benedittis, S., Sammarra, I., Bertoli, G., Labate, A., et al. (2022). Non-coding RNAs: new biomarkers and therapeutic targets for temporal lobe epilepsy. *Int. J. Mol. Sci.* 23:3063. doi: 10.3390/ijms23063063
- Moharamoghli, M., Hassan-Zadeh, V., Dolatshahi, E., Alizadeh, Z., and Farazmand, A. (2019). The expression of GAS5, THRIL, and RMRP lncRNAs is increased in T cells of patients with rheumatoid arthritis. *Clin. Rheumatol.* 38, 3073–3080. doi: 10.1007/s10067-019-04694-z
- Seki, T., Yamagata, H., Uchida, S., Chen, C., Kobayashi, A., Kobayashi, M., et al. (2019). Altered expression of long noncoding RNAs in patients with major depressive disorder. *J. Psychiatr. Res.* 117, 92–99. doi: 10.1016/j.jpsychires.2019.07.004
- Tang, Z. B., et al. (2022). LncRNA RMRP accelerates autophagy-mediated neurons apoptosis through miR-3142/TRIB3 signaling axis in alzheimer's disease. *Brain Res.* 1785:147884. doi: 10.1016/j.brainres.2022.147884
- Vezzani, A., Balosso, S., and Ravizza, T. (2008). The role of cytokines in the pathophysiology of epilepsy. *Brain Behav. Immun.* 22, 797–803. doi: 10.1016/j.bbi.2008.03.009
- Villa, C., Lavitrano, M., and Combi, R. (2019). Long non-coding RNAs and related molecular pathways in the pathogenesis of epilepsy. *Int. J. Mol. Sci.* 20:4898. doi: 10.3390/ijms20194898
- Wei, J., et al. (2022). The temporal and spatial changes of Th17, Tregs, and related cytokines in epilepsy lesions. *Appl. Bionics Biomech.* 2022:7871302. doi: 10.1155/2022/7871302
- Xu, D., Koh, S., and Miller, S. D. (2021). "Role of regulatory T cells in epilepsy" in *Inflammation and Epilepsy: New Vistas*, 203–219. doi: 10.1016/j.pneurobio.2022.102335
- Yue, J., Xu, R., Yin, C., Yang, H., Zhang, C., and Zhao, D. (2022). Negative effects of brain regulatory T cells depletion on epilepsy. *Prog. Neurobiol.* 217:102335. doi: 10.1016/j.pneurobio.2022.102335
- Zemmour, D., et al. (2017). Flicr, a long noncoding RNA, modulates Foxp3 expression and autoimmunity. *Proc. Natl. Acad. Sci.* 114, E3472–E3480. doi: 10.1073/pnas.1700946114
- Zhang, J., Han, Y., Zhao, Y., Li, Q., Jin, H., and Qin, J. (2019). Inhibition of TRIB3 protects against neurotoxic injury induced by Kainic acid in rats. *Front. Pharmacol.* 10:585. doi: 10.3389/fphar.2019.00585
- Zhao, C.-S., et al. (2022). LncRNA GAS5 promotes epilepsy progression through the epigenetic repression of miR-219, in turn affecting CaMKII γ /NMDAR pathway. *J. Neurogenet.* 36, 1–11. doi: 10.1080/01677063.2022.2067536